|
Inhibitor
|
Total no. of isolates
|
No. of drug-susceptible isolatesa
|
Percentage of drug-susceptible isolates correctly predicted by the algorithms
|
|---|
| | | |
DR_SEQAN
|
Retrogram
|
ANRS
|
HIVDB
|
RegaInst
|
|---|
|
Zidovudine (AZT)
|
135
|
48
|
79.2
|
64.6
|
72.9
|
68.8
|
72.9
|
|
Zalcitabine (ddC)
|
130
|
106
|
83.0
|
18.9
|
n.d.b
|
n.d.
|
24.5
|
|
Didanosine (ddI)
|
136
|
104
|
93.3
|
20.2
|
79.8
|
28.8
|
27.9
|
|
Lamivudine (3TC)
|
138
|
59
|
83.1
|
79.7
|
88.1
|
78.0
|
78.0
|
|
Stavudine (d4T)
|
136
|
85
|
60.0
|
38.8
|
41.2
|
37.6
|
67.1
|
|
Abacavir (ABC)
|
134
|
75
|
88.0
|
32.0
|
89.3
|
38.7
|
33.3
|
|
Nevirapine (NVP)
|
183
|
66
|
87.9
|
65.2
|
93.9
|
90.9
|
72.7
|
|
Delavirdine (DLV)
|
183
|
103
|
83.5
|
57.3
|
n.d.
|
82.5
|
58.3
|
|
Efavirenz (EFV)
|
180
|
97
|
79.4
|
48.5
|
67.0
|
64.9
|
49.5
|
|
Saquinavir (SQV)
|
548
|
278
|
65.8
|
73.4
|
89.9
|
73.4
|
80.9
|
|
Ritonavir (RTV)
|
510
|
237
|
67.9
|
75.1
|
84.0
|
88.6
|
77.2
|
|
Indinavir (IDV)
|
529
|
250
|
70.8
|
70.0
|
79.2
|
78.0
|
84.0
|
|
Nelfinavir (NFV)
|
567
|
224
|
66.1
|
70.5
|
80.4
|
73.7
|
77.7
|
|
Amprenavir (APV)
|
527
|
282
|
72.0
|
67.7
|
99.3
|
70.9
|
86.9
|
|
Lopinavir (LPV)
|
203
|
42 (99)
|
85.7 (43.4)
|
88.1 (60.6)
|
100 (87.9)
|
69.0 (29.3)
|
81.0 (45.5)
|
-
a Drug susceptible isolates were defined as those that in comparison with the wild-type reference clone showed a fold-increase of the IC50 value for each drug, which was below 1.8-fold for AZT, 2.6-fold for ddC, 2-fold for ddI and d4T, 9-fold for 3TC, 4.5-fold for ABC, 6-fold for NVP, DLV and EFV, 1.7-fold for SQV and LPV, 2.5-fold for RTV and IDV, 3.6-fold for NFV and 2-fold for APV. Those cut-off values were consistent with those previously defined for the PhenoSense™ assay [24]. In the case of LPV, the values shown between parenthesis refer to the clinically relevant cut-off value of 10-fold [24].
-
b n.d., not determined
